OOIR: Observatory of International Research

Papers

(The H4-Index of Drugs is 56. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Prevention and Treatment of Monkeypox	356
The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update	257
BNT162b2 mRNA COVID-19 Vaccine: First Approval	253
Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences	220
The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin	218
Inclisiran: First Approval	208
Lumasiran: First Approval	187
Nirmatrelvir Plus Ritonavir: First Approval	179
Acute Pancreatitis: Diagnosis and Treatment	176
Casimersen: First Approval	164
Aducanumab: First Approval	156
Sotorasib: First Approval	132
Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile I	125
TRPV1-Targeted Drugs in Development for Human Pain Conditions	120
Setmelanotide: First Approval	111
Managing Diabetic Foot Ulcers: Pharmacotherapy for Wound Healing	110
Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update	110
Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects	102
Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis	101
Nivolumab Plus Relatlimab: First Approval	89
Orelabrutinib: First Approval	86
REGN-EB3: First Approval	85
Deucravacitinib: First Approval	84
Amivantamab: First Approval	82
Lonafarnib: First Approval	81

Remimazolam: A Review in Procedural Sedation	80
Fabry Disease: The Current Treatment Landscape	78
Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder	78
Belzutifan: First Approval	75
Faricimab: First Approval	75
Abrocitinib: First Approval	71
Savolitinib: First Approval	70
Pralsetinib: First Approval	70
Disitamab Vedotin: First Approval	70
Vutrisiran: First Approval	69
Cannabinoid Formulations and Delivery Systems: Current and Future Options to Treat Pain	67
Nintedanib: A Review in Fibrotic Interstitial Lung Diseases	66
Tisotumab Vedotin: First Approval	65
Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations	64
Molnupiravir: First Approval	63
Cadonilimab: First Approval	63
Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics	62
MicroRNA Mimics or Inhibitors as Antiviral Therapeutic Approaches Against COVID-19	61
Telitacicept: First Approval	60
Casirivimab/Imdevimab: First Approval	60
Current Status of Clinical Trials on Tau Immunotherapies	60
Trilaciclib: First Approval	60
Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections	60
Efgartigimod: First Approval	59
Contezolid: First Approval	58
Targeting AMPK by Statins: A Potential Therapeutic Approach	57
Lecanemab: First Approval	57
Loncastuximab Tesirine: First Approval	57
Third-Generation Antiseizure Medications for Adjunctive Treatment of Focal-Onset Seizures in Adults: A Systematic Review and Network Meta-analysis	57
Infigratinib: First Approval	57
Tebentafusp: First Approval	57
Imipenem/Cilastatin/Relebactam: A Review in Gram-Negative Bacterial Infections	56